In the BioHarmony Drug Report Database
Cyramza (ramucirumab) is an antibody pharmaceutical. Ramucirumab was first approved as Cyramza on 2014-04-21. It is used to treat colorectal neoplasms, non-small-cell lung carcinoma, and stomach neoplasms in the USA. It has been approved in Europe to treat stomach neoplasms. The pharmaceutical is active against vascular endothelial growth factor receptor 2.
Image (chem structure or protein)